Galmed Pharma Secures Up to $10M Equity Line with Yorkville
Ticker: GLMD · Form: 6-K · Filed: Aug 30, 2024 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Aug 30, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $10.0 million, $15,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: equity-financing, capital-raise, standby-agreement
TL;DR
Galmed just inked a $10M equity line with Yorkville, giving them cash flexibility.
AI Summary
On August 30, 2024, Galmed Pharmaceuticals Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville). Under this agreement, Galmed has the option to sell up to $10.0 million of its ordinary shares to Yorkville over time.
Why It Matters
This agreement provides Galmed with potential access to capital, offering financial flexibility for its operations and development programs.
Risk Assessment
Risk Level: medium — Standby equity agreements can dilute existing shareholders and may indicate the company is seeking capital due to operational needs.
Key Numbers
- $10.0 million — Standby Equity Purchase Facility (Maximum capital Galmed can raise from Yorkville)
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Company entering the agreement
- YA II PN, LTD. (company) — Investor in the agreement
- Yorkville (company) — Alternative name for YA II PN, LTD.
- $10.0 million (dollar_amount) — Maximum amount available under the agreement
- August 30, 2024 (date) — Date the agreement was entered into
FAQ
What is the purpose of the Standby Equity Purchase Agreement?
The agreement allows Galmed Pharmaceuticals Ltd. to sell up to $10.0 million of its ordinary shares to YA II PN, LTD. (Yorkville) from time to time, providing potential access to capital.
Who is YA II PN, LTD. (Yorkville)?
Yorkville is identified as a Cayman Islands exempt limited partnership that has entered into the Standby Equity Purchase Agreement with Galmed Pharmaceuticals Ltd.
What is the maximum amount Galmed can raise under this agreement?
Galmed has the right to sell up to $10.0 million of its ordinary shares to Yorkville under the terms of the Purchase Agreement.
When was this agreement entered into?
The Standby Equity Purchase Agreement was entered into on August 30, 2024.
Does Galmed have an obligation to sell shares under this agreement?
No, the agreement states that Galmed has the right, but not the obligation, to sell shares to Yorkville.
Filing Stats: 1,113 words · 4 min read · ~4 pages · Grade level 15.5 · Accepted 2024-08-30 16:15:20
Key Financial Figures
- $10.0 million — rrence, an “Advance”) up to $10.0 million (the “Commitment Amount”) o
- $15,000 — es”) to Yorkville and also paid a $15,000 structuring fee to an affiliate of York
Filing Documents
- form6-k.htm (6-K) — 27KB
- ex10-1.htm (EX-10.1) — 308KB
- 0001493152-24-034594.txt ( ) — 335KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: August 30, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer